|1.||Smith, Amos B: 4 articles (12/2015 - 08/2007)|
|2.||Ai, Yanran: 1 article (12/2015)|
|3.||Kozytska, Mariya V: 1 article (12/2015)|
|4.||Khartulyari, Anton S: 1 article (12/2015)|
|5.||Zou, Yike: 1 article (12/2015)|
|6.||Alborzinia, Hamed: 1 article (08/2011)|
|7.||Ott, Ingo: 1 article (08/2011)|
|8.||Wölfl, Stefan: 1 article (08/2011)|
|9.||Bieda, Ruth: 1 article (08/2011)|
|10.||Meyer, Andreas: 1 article (08/2011)|
|1.||AIDS-Related Complex (ARC)
12/16/2015 - "Highlights include an unprecedented late-stage large-fragment Petasis-Ferrier union/rearrangement, a multicomponent Type I Anion Relay Chemistry (ARC) tactic, and a dithiane-epoxide union in conjunction with an oxazole-directed stereoselective reduction. "
08/16/2007 - "Central to this venture was the use of four dithiane unions, including the highly effective deployment of the anion relay chemistry (ARC) tactic recently introduced by our laboratory."
07/01/2011 - "The successful strategy entails a modular approach to all possible stereoisomers of the selected piperidine scaffold, exploiting Type II Anion Relay Chemistry (ARC), followed in turn by intramolecular S(N)2 cyclization, chemoselective removal of the dithiane moieties and carbonyl reductions."
12/18/2008 - "Highlights include implementation of multicomponent type I anion relay chemistry (ARC) to unite 2-TBS-1,3-dithiane with two epoxides to construct the eastern hemisphere, a late-stage dithiane union to secure the complete, fully functionalized carbon backbone, and Yamaguchi macrolactonization, which led to (-)-2-epi-peloruside A via an unexpected epimerization at C(2)."
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/1999 - "We have utilized an anti-AP-1 retinoid [2-(4,4-dimethyl-3,4-dihydro-2H-1 benzopyran-6-yl)carbonyl-2-(4-carboxyphenyl)-1,3,-dithiane; SR11238], which does not transactivate through a retinoic acid response element (RARE), and a potent vitamin D3 analogue [1alpha,25(OH)2-16-ene-23-yne-26,27-F6-19-nor-D3, code name LH] together at low, physiologically safer doses against a panel of prostate cancer cell lines that represent progressively more transformed phenotypes. "
|1.||Tretinoin (Retinoic Acid)
|2.||Epoxy Compounds (Epoxides)
|3.||Cholecalciferol (Vitamin D3)
|8.||bipiperidyl mustard (BPM)